Glaukos Corporation (FRA:6GJ)

Market Cap	5.87B -29.4%
Revenue (ttm)	432.19M +32.3%
Net Income	-159.86M
EPS	-2.80
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	98.50
Previous Close	101.00
Day's Range	98.50 - 98.50
52-Week Range	63.50 - 152.00
Beta	n/a
RSI	54.52
Earnings Date	Feb 17, 2026

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and ...

• Industry: Surgical and Medical Instruments and Apparatus
• Founded: 1998
• Employees: 995
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6GJ

Financial Performance

In 2025, Glaukos's revenue was $507.44 million, an increase of 32.33% compared to the previous year's $383.48 million. Losses were -$187.69 million, 28.2% more than in 2024.

Financial numbers in USD